Phathom Pharmaceuticals (PHAT) Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Revenue for 4 consecutive years, with $74.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Revenue rose 88.02% year-over-year to $74.3 million; the TTM figure through Jun 2026 stood at $239.7 million (up 110.16% YoY), while the FY2025 annual figure was $175.1 million, up 216.93% from the prior year.
• Revenue grew to $74.3 million in Q2 2026 per PHAT's latest filing, from $58.3 million in the prior quarter.
• Across five years, Revenue topped out at $74.3 million in Q2 2026 and bottomed at $682000.0 in Q4 2023.
• Historically, Revenue has averaged $33.1 million across 4 years, with a median of $29.7 million in 2024.
• Annual changes were most pronounced in 2024 — Revenue jumped 4249.56% — and 2026, when it soared 88.02%.
• Phathom Pharmaceuticals' Revenue stood at $682000.0 in 2023, then surged by 4249.56% to $29.7 million in 2024, then soared by 94.12% to $57.6 million in 2025, then increased by 28.98% to $74.3 million in 2026.
• Business Quant data shows PHAT's Revenue at $74.3 million in Q2 2026, $58.3 million in Q1 2026, and $57.6 million in Q4 2025.